This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard H. Myers, PhD; Daniel S. Sax, MD; Walter J. Koroshetz, MD; Carol Mastromauro, MSW; L. Adrienne Cupples, PhD; Dan K. Kiely, MA, MPH; Florence K. Pettengill; Edward D. Bird, MD

Arch Neurol. 1991;48(8):800-804.

Abstract
• The rate of disease progression was assessed for 42 persons affected by Huntington's disease who had been neurologically examined at least six times and followed up for at least 3 years. Disease progression was assessed by a disability rating scale administered at each examination. Slow progression was associated with older age at onset of disease and with heavier weight (body mass index) at the first examination. Men tended to have a slower disease progression than did women, and this was particularly evident among men inheriting Huntington's disease from affected mothers. Neither the butyrophenone haloperidol nor the tricyclic antidepressant imipramine were related to rate of progression. Assessments of depression, hostility, and tobacco use were also unrelated to rate of progression. Clinical trials in Huntington's disease should consider these factors when designing therapeutic studies.

Author Affiliations
From the Departments of Neurology, Boston (Mass) University School of Medicine (Drs Myers and Sax, Mr Kiely, and Ms Pettengill), and Massachusetts General Hospital, Harvard Medical School, Boston (Drs Myers, Koroshetz, and Bird and Ms Mastromauro); the School of Public Health, Boston University, (Dr Cupples); and the Mailman Research Center, McLean Hospital, Belmont, Mass (Dr Bird).

Footnotes
Accepted for publication February 19, 1991.

Reprint requests to Department of Neurology, Boston University School of Medicine, 30 E Concord St, Boston, MA 02118 (Dr Myers).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models
Phan et al.
Hum Mol Genet 2009;18:1006-1016.
ABSTRACT | FULL TEXT  

Weight loss in Huntington disease increases with higher CAG repeat number
Aziz et al.
Neurology 2008;71:1506-1513.
ABSTRACT | FULL TEXT  

Striosomes and mood dysfunction in Huntington's disease
Tippett et al.
Brain 2007;130:206-221.
ABSTRACT | FULL TEXT  

Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin
Cyr et al.
FASEB J. 2006;20:2541-2543.
ABSTRACT | FULL TEXT  

The association of CAG repeat length with clinical progression in Huntington disease
Rosenblatt et al.
Neurology 2006;66:1016-1020.
ABSTRACT | FULL TEXT  

Gene expression in Huntington's disease skeletal muscle: a potential biomarker
Strand et al.
Hum Mol Genet 2005;14:1863-1876.
ABSTRACT | FULL TEXT  

Rate and correlates of weight change in Huntington's disease
Hamilton et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:209-212.
ABSTRACT | FULL TEXT  

Huntington's disease: Clinical correlates of disability and progression
Mahant et al.
Neurology 2003;61:1085-1092.
ABSTRACT | FULL TEXT  

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course
Squitieri et al.
Brain 2003;126:946-955.
ABSTRACT | FULL TEXT  

Weight loss in early stage of Huntington's disease
Djousse et al.
Neurology 2002;59:1325-1330.
ABSTRACT | FULL TEXT  

Rate of functional decline in Huntington's disease
Marder et al.
Neurology 2000;54:452-452.
ABSTRACT | FULL TEXT  

Differences in duration of Huntington's disease based on age at onset
Foroud et al.
J. Neurol. Neurosurg. Psychiatry 1999;66:52-56.
ABSTRACT | FULL TEXT  

Severity of Cognitive Impairment in Juvenile and Late-Onset Huntington Disease
Gomez-Tortosa et al.
Arch Neurol 1998;55:835-843.
ABSTRACT | FULL TEXT  

Clinical and Magnetic Resonance Features of the Classic and Akinetic-Rigid Variants of Huntington's Disease
Oliva et al.
Arch Neurol 1993;50:17-19.
ABSTRACT  

Weight Loss in Huntington's Disease
Kremer and Roos
Arch Neurol 1992;49:349-349.
ABSTRACT